Journal article icon

Journal article

Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.

Abstract:

BACKGROUND: Selective cyclooxygenase inhibitors may retard the progression of cancer, but they have enhanced thrombotic potential. We report on cardiovascular adverse events in patients receiving rofecoxib to reduce rates of recurrence of colorectal cancer. METHODS: All serious adverse events that were cardiovascular thrombotic events were reviewed in 2434 patients with stage II or III colorectal cancer participating in a randomized, placebo-controlled trial of rofecoxib, 25 mg daily, starte...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1056/nejmoa071841

Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, RDM, Clinical Lab Sciences, Biomedical Research Centre
Role:
Author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Oncology
Role:
Author
Expand authors...
Journal:
The New England journal of medicine
Volume:
357
Issue:
4
Pages:
360-369
Publication date:
2007-07-05
DOI:
EISSN:
1533-4406
ISSN:
0028-4793
URN:
uuid:31fef9bc-be5e-4ba2-82df-c263f9deacef
Source identifiers:
134229
Local pid:
pubs:134229

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP